"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Descriptor ID |
D002945
|
MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 4 | 8 |
1995 | 3 | 8 | 11 |
1996 | 3 | 8 | 11 |
1997 | 3 | 8 | 11 |
1998 | 3 | 9 | 12 |
1999 | 1 | 6 | 7 |
2000 | 2 | 6 | 8 |
2001 | 1 | 8 | 9 |
2002 | 4 | 5 | 9 |
2003 | 2 | 5 | 7 |
2004 | 4 | 7 | 11 |
2005 | 5 | 12 | 17 |
2006 | 2 | 7 | 9 |
2007 | 1 | 6 | 7 |
2008 | 2 | 10 | 12 |
2009 | 2 | 7 | 9 |
2010 | 1 | 8 | 9 |
2011 | 1 | 14 | 15 |
2012 | 4 | 6 | 10 |
2013 | 2 | 6 | 8 |
2014 | 0 | 7 | 7 |
2015 | 3 | 4 | 7 |
2016 | 6 | 8 | 14 |
2017 | 2 | 4 | 6 |
2018 | 5 | 6 | 11 |
2019 | 5 | 5 | 10 |
2020 | 7 | 9 | 16 |
2021 | 5 | 6 | 11 |
2022 | 0 | 7 | 7 |
2023 | 1 | 7 | 8 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
-
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.
-
Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical Cancer. J Clin Oncol. 2023 10 10; 41(29):4603-4604.
-
Regression of ovarian cancer xenografts by depleting or inhibiting RLIP. Biochem Pharmacol. 2023 11; 217:115847.
-
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. Eur Urol Oncol. 2024 Feb; 7(1):83-90.
-
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO Precis Oncol. 2023 07; 7:e2300095.
-
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 09 01; 41(25):4107-4117.
-
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
-
Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv. 2023 02; 17(1):27-39.
-
Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2023 04; 34(4):702-709.